Latanogan (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye, triggering remodeling of the extracellular matrix in the ciliary body. This enhances uveoscleral outflow of aqueous humor, leading to a reduction in intra‑ocular pressure.

The prescribed regimen is one drop of Latanogan in the affected eye(s) once daily, typically in the evening. The exact dosing schedule is determined by the treating ophthalmologist based on individual patient needs.

The safety of latanoprost in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and only under medical supervision.

To place an order, submit an enquiry on the Latanogan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanogan (latanoprost) belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong IOP‑lowering efficacy. Compared with beta‑blocker drops such as timolol, latanoprost often provides greater pressure reduction with a different side‑effect profile, including ocular hyperemia and increased eyelash growth.

Store Latanogan at room temperature, below 25 °C, in the original container. Protect the bottle from light and moisture, and keep it out of reach of children. Do not freeze the product.

Wash your hands, tilt the head back, and gently pull down the lower eyelid to create a small pocket. Squeeze one drop into the conjunctival sac without touching the tip to the eye or lashes. Close the eye gently for a few minutes and avoid blinking excessively.

Serious risks, though rare, include uveitis (eye inflammation), macular edema (central retinal swelling), and severe allergic reactions such as swelling or rash. Patients should seek immediate medical attention if they experience persistent eye pain, sudden vision changes, or signs of inflammation.

Latanogan is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation, and in eyes with active intra‑ocular inflammation or infection. Caution is advised for individuals with a history of uveitis or severe ocular surface disease.